Skin
| INDICATIONS |
PrednisTab is intended for use in dogs. The indications for PrednisTab are the same as those for other anti-inflammatory steroids and comprise the various collagen, dermal, allergic, ocular, otic, and musculoskeletal conditions known to be responsive to the anti-inflammatory corticosteroids. Representative of the conditions in which the use of steroid therapy and the benefits to be derived therefrom have had repeated confirmation in the veterinary literature are: (1) dermal conditions, such as nonspecific eczema, summer dermatitis, and burns; (2) allergic manifestations, such as acute urticaria, allergic dermatitis, drug and serum reactions, bronchial asthma, and pollensensitivities; (3) ocular conditions, such as iritis, iridocyclitis, secondary glaucoma, (4) otic conditions, such as otitis externa; (5) musculoskeletal conditions, such as myositis, rheumatoid arthritis, osteoarthritis, and bursitis; (6)various chronic or recurrent diseases of unknown etiology such as ulcerative colitis and nephrosis. In acute adrenal insufficiency, prednisolone may be effective because of its ability to correct the defect in carbohydrate metabolism and relieve the impaired diuretic response to water, characteristic of primary or secondary adrenal insufficiency. However, because this agent lacks significant mineralocorticoid activity, hydrocortisone sodium succinate, hydrocortisone, or cortisone should be used when salt retention is indicated. |
| CONTRAINDICATIONS | Do not use in viral infections. Prednisolone, like methylprednisolone, is contraindicated in animals with peptic ulcer, corneal ulcer, and Cushingoid syndrome. The presence of diabetes, osteoporosis, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency, and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs but should be kept in mind. |
| ADMINISTRATION | The keystone of satisfactory therapeutic management with PrednisTab prednisolone tablets, as with other steroid predecessors, is individualization of dosage in reference to the severity of the disease, the anticipated duration of steroid therapy, and the animal patient's threshold or tolerance for steroid excess. The prime objective of steroid therapy should be to achieve a satisfactory degree of control with a minimum effective daily dose. The dosage recommendations are suggested average total daily doses and areintended as guides. As with other orally administered corticosteroids, the total daily doseof prednisolone should be given in equally divided doses. The initial suppressive doselevel is continued until a satisfactory clinical response is obtained, a period usually of 2 to7 days in the case of musculoskeletal diseases, allergic conditions affecting the skin orrespiratory tract, and ocular inflammatory diseases. If a satisfactory response is notobtained in 7 days, reevaluation of the case to confirm the original diagnosis should bemade. As soon as a satisfactory clinical response is obtained, the daily dose should bereduced gradually, either to termination of treatment in the case of acute conditions(e.g., seasonal asthma, dermatitis, acute ocular inflammations) or to the minimaleffective maintenance dose level in the case of chronic conditions (e.g., rheumatoidarthritis). In chronic conditions, and in rheumatoid arthritis especially, it is important thatthe reduction in dosage from initial to maintenance dose levels be accomplished slowly. The maintenance dose level should be adjusted from time to time as required byfluctuation in the activity of the disease and the animal's general status. Accumulatedexperience has shown that the long-term benefits to be gained from continued steroidm maintenance are probably greater the lower the maintenance dose level. In rheumatoidarthritis in particular, maintenance steroid therapy should be at the lowest possible level. |
2.5 mg per 10 lb (4.5 kg) body weight per day. Average total daily oral doses for dogs as follows:
5 to 20 lb (2 to 9 kg) body weight 1.25 to 5 mg
20 to 40 lb (9 to 18 kg) body weight 5 to 10 mg
40 to 80 lb (18 to 36 kg) body weight 10 to 20 mg
80 to 160 lb (36 to 73 kg) body weight 20 to 40 mg
The total daily dose should be given in divided doses, 6 to 10 hours apart.
HOW SUPPLIED
PrednisTab is available as 5 mg compressed quarter-scored tablets in bottles of 1000 and 20 mg compressed quarter-scored tablets in bottles of 500.
STORAGE
Store at controlled room temperature 20° - 25° C (68° - 77° F), excursions permittedbetween 15°- 30° C (59° - 86° F)
